Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

2(40.0%)

Phase 2

2(40.0%)

Phase 4

1(20.0%)

5Total

N/A(2)

Phase 2(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT03382769Not ApplicableTerminated

Hearing Loss in Older Adults Study

Role: collaborator

NCT04148391Phase 2Active Not Recruiting

NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)

Role: collaborator

NCT02623946Completed

Motor Evoked Potentials as a Biomarker in Alemtuzumab Treated Multiple Sclerosis Patients

Role: collaborator

NCT03625453Phase 2Completed

Study of ABX-1431 in Adult Patients With Tourette Syndrome or Chronic Motor Tic Disorder

Role: collaborator

NCT01658384Completed

Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients

Role: collaborator

NCT02146534Phase 4Completed

Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients

Role: collaborator

NCT02383550Completed

Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients - A Three Year Extension

Role: collaborator

NCT00165971Not ApplicableCompleted

Recovery From General Anesthesia

Role: collaborator

All 8 trials loaded